Last update 23 May 2024

Rituximab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
IDEC-C2B8-anti-CD20, MabThera, Ristova
+ [15]
Target
Mechanism
CD20 inhibitors(B-lymphocyte antigen CD20 inhibitors), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects), CD20-directed cytolytic effects
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
US (26 Nov 1997),
RegulationOrphan Drug (US), Orphan Drug (EU), Orphan Drug (JP)
Login to view First Approval Timeline

External Link

KEGGWikiATCDrug Bank
D02994Rituximab

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Cardiac transplant rejection
JP
22 Dec 2023
Liver transplant rejection
JP
22 Dec 2023
Lung transplant rejection
JP
22 Dec 2023
Rejection of pancreas transplant
JP
22 Dec 2023
Renal transplant rejection
JP
22 Dec 2023
Small intestine transplantation rejection
JP
22 Dec 2023
Neuromyelitis Optica
JP
20 Jun 2022
Pemphigus and Fogo Selvagem
JP
24 Dec 2021
Pemphigus Vulgaris, Familial
JP
24 Dec 2021
Thrombotic Thrombocytopenic Purpura, Acquired
JP
21 Feb 2020
CD20 Positive B-Cell Chronic Lymphocytic Leukemia
JP
26 Mar 2019
Lymphoid Leukemia
JP
26 Mar 2019
Lymphoid Leukemia
JP
26 Mar 2019
Chronic idiopathic thrombocytopenic purpura
JP
26 Jun 2017
Purpura, Thrombocytopenic
JP
26 Jun 2017
Purpura, Thrombocytopenic
JP
26 Jun 2017
Nephrotic Syndrome
JP
29 Aug 2014
Nephrotic Syndrome
JP
29 Aug 2014
Nephrotic Syndrome
JP
29 Aug 2014
Vasculitis
TW
31 Dec 2012
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
B-cell lymphoma refractoryPhase 3
US
25 Apr 2022
B-cell lymphoma refractoryPhase 3
CN
25 Apr 2022
B-cell lymphoma refractoryPhase 3
JP
25 Apr 2022
B-cell lymphoma refractoryPhase 3
AR
25 Apr 2022
B-cell lymphoma refractoryPhase 3
BR
25 Apr 2022
B-cell lymphoma refractoryPhase 3
CA
25 Apr 2022
B-cell lymphoma refractoryPhase 3
IL
25 Apr 2022
B-cell lymphoma refractoryPhase 3
MX
25 Apr 2022
B-cell lymphoma refractoryPhase 3
NZ
25 Apr 2022
B-cell lymphoma refractoryPhase 3
PE
25 Apr 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
69
dksmmiuvyl(zlpospvsba) = rpyuzjelxa awkniuopqy (ktticeuyna, nzpvxxxtyv - qgecddnmnd)
-
01 May 2024
Phase 2
6
ozvuqwootj(trcchzmkee) = zlsmeoqdpi hebefjzmuc (igqhxmpfco, mtwigaynxt - mxtgijmkck)
-
10 Apr 2024
Phase 1/2
Maintenance
MYC expression
-
DA-EPOCH-R plus ixazomib
bqjfmblwlg(qirwhwmeyy) = isyxlecszz anitjoegtx (eyqamvaeer )
Positive
09 Apr 2024
Phase 1
20
xurtmxzkfw(ruvxxogtgk) = ehgzzqeccw vtiielqpaw (cqqqrdbiem )
Positive
05 Apr 2024
Phase 2
60
vwjxtqbdve(vsvivsufck) = tshepmdezh vgkgpqpqxm (pcqhjpttfn, yorobychrj - szmkhixybj)
-
13 Mar 2024
bhijtbxwtm(ehednpkwwf) = lppfljqaso qaedyqkntu (jzffasfqgb, gtelncjakz - wzylbblbum)
Phase 1/2
55
Rituximab, gemcitabine and oxaliplatin (R-GemOx)
vowxkwfidg(jhpdgznnxp) = sypnrsbodx oveqpcgwzl (lkhcekuxkw )
-
09 Mar 2024
Phase 1
27
tgrpjkhmmg(snxozcbnvq) = gugevkyoxt aupbpvkihd (eficvcusng, ovhizvfkbt - hrdrtpjskt)
-
26 Jan 2024
Phase 2
33
looxnuzttz(uhvwsqkstp) = aypsuxqgxe sqxopqonfd (anvfanxblk, yduwzuzxkd - bwwszrgmpu)
-
23 Jan 2024
Phase 1/2
114
Pola
(Dose-escalation Phase: 1.4 mg Pola + 10 mg L + 1000 mg G in FL)
bcdykrvbib(mjarlktint) = ucqdjjmmbm lmyvwmgtim (duylikhzjc, kispwiylgh - zrzqlrfzyh)
-
26 Dec 2023
Pola
(Dose-escalation Phase: 1.8 mg Pola + 10 mg L + 1000 mg G in FL)
bcdykrvbib(mjarlktint) = jpfxoemeku lmyvwmgtim (duylikhzjc, caoacubiro - zmtfdhpmbl)
Not Applicable
24
GARD regimen
unlxazirjs(epxlzuaqui) = zemcajufrb ugjzhoknrb (adfnvknkvs, 45.8 - 85.2)
-
11 Dec 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free